Atherosclerosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnosis, By Treatment, By Route of Administration, By End User, By Region and Competition, 2020-2030F

Description

The Global Atherosclerosis Drugs Market was valued at USD 18.85 billion in 2024 and is projected to reach USD 22.84 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.21% during the forecast period. Atherosclerosis, a condition characterized by the narrowing and hardening of arteries due to fatty plaque accumulation, continues to be a significant global health issue. It is a leading cause of heart disease, stroke, and other cardiovascular complications, resulting in millions of deaths annually. The market for atherosclerosis drugs has seen substantial growth, driven by the increasing prevalence of this condition.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 18.85 Billion
Market Size 2030	USD 22.84 Billion
CAGR 2025-2030	3.21%
Fastest Growing Segment	Hospitals & Clinics
Largest Market	North America

Unhealthy lifestyle factors such as poor diet, physical inactivity, and smoking are major contributors to the rising incidence of atherosclerosis worldwide, leading to a large patient population in need of treatment. Furthermore, the aging global population is at higher risk, which is expected to drive demand for atherosclerosis medications. Advances in medical technology and diagnostics have enabled earlier detection, facilitating more timely interventions and treatments. Public health campaigns and increasing awareness about cardiovascular health have also encouraged more individuals to seek treatment.

While the Global Atherosclerosis Drugs Market presents significant opportunities, it also faces challenges. With the rising burden of atherosclerosis, ongoing innovation and research are critical to developing effective therapies. Personalized medicine and targeted treatments show promise in improving patient outcomes. However, challenges related to drug pricing, patient adherence, and growing competition must be addressed to ensure accessibility for those in need. The collaboration between pharmaceutical companies, healthcare providers, and policymakers will be essential to combating atherosclerosis and its impact on global health.

Key Market Drivers

Rising Prevalence of Atherosclerosis

Atherosclerosis, characterized by plaque buildup in arteries, is becoming more widespread worldwide. This condition significantly increases the risk of heart attacks, strokes, and other cardiovascular diseases, making it a global healthcare priority. As modern lifestyles contribute to obesity, hypertension, and high cholesterol, the need for effective treatments for atherosclerosis is intensifying. Diets high in saturated fats, trans fats, and processed foods, common in many regions, further exacerbate the risk factors. Additionally, atherosclerosis is more prevalent in older individuals, and as the global population ages, the incidence of this condition is expected to rise, further stressing healthcare systems. Tobacco use and diabetes are also major contributors to the increasing prevalence of atherosclerosis.

Recent research has uncovered cancer-like features in atherosclerosis, highlighting potential new treatment avenues. Studies supported by the National Institutes of Health (NIH) suggest that smooth muscle cells in arteries may take on characteristics similar to cancer cells, worsening the condition. This discovery opens the door for novel therapies, such as using anti-cancer drugs to target these tumor-like processes, offering hope for more effective treatments.

Key Market Challenges

Increasing Competition

The atherosclerosis drugs market is highly competitive, with numerous established pharmaceutical companies and emerging players vying for market share. Major pharmaceutical companies like Pfizer, AstraZeneca, and Merck have dominated the market for years, benefiting from blockbuster drugs such as Lipitor (atorvastatin) and Crestor (rosuvastatin). However, newer entrants are introducing innovative therapies and specialized drug formulations targeting different aspects of atherosclerosis treatment. These companies are focusing on niche areas such as LDL cholesterol reduction or inflammation to address unmet needs in the market.

The rise of biosimilars and generics has further intensified competition, as these cost-effective alternatives to branded drugs become more prevalent. Smaller companies or startups face challenges related to regulatory approvals, clinical trials, and securing adequate funding. The dominance of established market leaders adds to the difficulty for newcomers to differentiate themselves. To remain competitive, companies must focus on innovation, whether through new drug formulations, strategic partnerships, or acquisitions.

Key Market Trends

Technological Advancements

Technological progress in healthcare is revolutionizing the development, diagnosis, and treatment of atherosclerosis, which is contributing to the growth of the market. Modern imaging technologies such as CT angiography, MRI, and intravascular ultrasound (IVUS) provide high-resolution images of blood vessels, enabling more accurate assessment of plaque buildup and its severity. Additionally, blood tests that incorporate biomarkers like high-sensitivity C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) aid in the early detection and risk assessment of atherosclerosis.

Artificial intelligence (AI) and machine learning are also enhancing the diagnosis of atherosclerosis by analyzing medical imaging and patient data to identify patterns and predict disease progression. These advancements are improving both the accuracy and efficiency of diagnosing atherosclerosis, contributing to better patient outcomes.

Key Market Players

F. Hoffmann-La Roche Ltd
Novartis AG
Merck & Co. Inc.
Pfizer Inc.
Eli Lilly and Co.
Sanofi S.A.
AstraZeneca Plc
Bayer AG
Regeneron Pharmaceuticals Inc.
GSK Plc

Report Scope

This report segments the Global Atherosclerosis Drugs Market into the following categories:

Diagnosis
Ankle-brachial Index
Doppler Ultrasound
Echocardiogram
Electrocardiogram
Blood Tests
Others
Treatment
Medication
Surgery
Others
Route of Administration
Oral
Parenteral
Others
End User
Hospitals & Clinics
Ambulatory Care Centers
Others
Region
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE

Competitive Landscape

The report includes detailed profiles of major companies in the atherosclerosis drugs market, offering insights into their market strategies and financial performance.

Available Customizations

The Global Atherosclerosis Drugs Market report can be customized to meet specific company needs, including detailed analysis and profiling of additional market players (up to five).

Product Code: 18828

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Atherosclerosis Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Diagnosis (Ankle-brachial Index, Doppler Ultrasound, Echocardiogram, Electrocardiogram, Blood Tests, Others)
- 5.2.2. By Treatment (Medication, Surgery, Others)
- 5.2.3. By Route of Administration (Oral, Parenteral, Others)
- 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others),By Region
- 5.2.5. By Region
- 5.2.6. By Company (2024)
5.3. Market Map

6. North America Atherosclerosis Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Diagnosis
- 6.2.2. By Treatment
- 6.2.3. By Route of Administration
- 6.2.4. By End User
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Atherosclerosis Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Diagnosis
    - 6.3.1.2.2. By Treatment
    - 6.3.1.2.3. By Route of Administration
    - 6.3.1.2.4. By End User
- 6.3.2. Canada Atherosclerosis Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Diagnosis
    - 6.3.2.2.2. By Treatment
    - 6.3.2.2.3. By Route of Administration
    - 6.3.2.2.4. By End User
- 6.3.3. Mexico Atherosclerosis Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Diagnosis
    - 6.3.3.2.2. By Treatment
    - 6.3.3.2.3. By Route of Administration
    - 6.3.3.2.4. By End User

7. Europe Atherosclerosis Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Diagnosis
- 7.2.2. By Treatment
- 7.2.3. By Route of Administration
- 7.2.4. By End User
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Atherosclerosis Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Diagnosis
    - 7.3.1.2.2. By Treatment
    - 7.3.1.2.3. By Route of Administration
    - 7.3.1.2.4. By End User
- 7.3.2. United Kingdom Atherosclerosis Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Diagnosis
    - 7.3.2.2.2. By Treatment
    - 7.3.2.2.3. By Route of Administration
    - 7.3.2.2.4. By End User
- 7.3.3. Italy Atherosclerosis Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Diagnosis
    - 7.3.3.2.2. By Treatment
    - 7.3.3.2.3. By Route of Administration
    - 7.3.3.2.4. By End User
- 7.3.4. France Atherosclerosis Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Diagnosis
    - 7.3.4.2.2. By Treatment
    - 7.3.4.2.3. By Route of Administration
    - 7.3.4.2.4. By End User
- 7.3.5. Spain Atherosclerosis Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Diagnosis
    - 7.3.5.2.2. By Treatment
    - 7.3.5.2.3. By Route of Administration
    - 7.3.5.2.4. By End User

8. Asia-Pacific Atherosclerosis Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Diagnosis
- 8.2.2. By Treatment
- 8.2.3. By Route of Administration
- 8.2.4. By End User
- 8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Atherosclerosis Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Diagnosis
    - 8.3.1.2.2. By Treatment
    - 8.3.1.2.3. By Route of Administration
    - 8.3.1.2.4. By End User
- 8.3.2. India Atherosclerosis Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Diagnosis
    - 8.3.2.2.2. By Treatment
    - 8.3.2.2.3. By Route of Administration
    - 8.3.2.2.4. By End User
- 8.3.3. Japan Atherosclerosis Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Diagnosis
    - 8.3.3.2.2. By Treatment
    - 8.3.3.2.3. By Route of Administration
    - 8.3.3.2.4. By End User
- 8.3.4. South Korea Atherosclerosis Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Diagnosis
    - 8.3.4.2.2. By Treatment
    - 8.3.4.2.3. By Route of Administration
    - 8.3.4.2.4. By End User
- 8.3.5. Australia Atherosclerosis Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Diagnosis
    - 8.3.5.2.2. By Treatment
    - 8.3.5.2.3. By Route of Administration
    - 8.3.5.2.4. By End User

9. South America Atherosclerosis Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Diagnosis
- 9.2.2. By Treatment
- 9.2.3. By Route of Administration
- 9.2.4. By End User
- 9.2.5. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Atherosclerosis Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Diagnosis
    - 9.3.1.2.2. By Treatment
    - 9.3.1.2.3. By Route of Administration
    - 9.3.1.2.4. By End User
- 9.3.2. Argentina Atherosclerosis Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Diagnosis
    - 9.3.2.2.2. By Treatment
    - 9.3.2.2.3. By Route of Administration
    - 9.3.2.2.4. By End User
- 9.3.3. Colombia Atherosclerosis Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Diagnosis
    - 9.3.3.2.2. By Treatment
    - 9.3.3.2.3. By Route of Administration
    - 9.3.3.2.4. By End User

10. Middle East and Africa Atherosclerosis Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Diagnosis
- 10.2.2. By Treatment
- 10.2.3. By Route of Administration
- 10.2.4. By End User
- 10.2.5. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Atherosclerosis Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Diagnosis
    - 10.3.1.2.2. By Treatment
    - 10.3.1.2.3. By Route of Administration
    - 10.3.1.2.4. By End User
- 10.3.2. Saudi Arabia Atherosclerosis Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Diagnosis
    - 10.3.2.2.2. By Treatment
    - 10.3.2.2.3. By Route of Administration
    - 10.3.2.2.4. By End User
- 10.3.3. UAE Atherosclerosis Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Diagnosis
    - 10.3.3.2.2. By Treatment
    - 10.3.3.2.3. By Route of Administration
    - 10.3.3.2.4. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. F. Hoffmann-La Roche Ltd
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
14.2. Novartis AG
14.3. Merck & Co. Inc.
14.4. Pfizer Inc.
14.5. Eli Lilly and Co.
14.6. Sanofi S.A.
14.7. AstraZeneca Plc
14.8. Bayer AG
14.9. Regeneron Pharmaceuticals Inc.
14.10. GSK Plc